Amylyx Pharmaceuticals, Inc.
AMLXNASDAQ
Healthcare
Biotechnology
$15.02
+0.67(4.66%)
52W $3.31 – $16.92
AI-generated
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
$1.2BMkt Cap
—Rev TTM
-$127MNI TTM
-8.8xP/E TTM
What Changed Recently
Fundamentals
How The Business Makes Money
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Industry Biotechnology
Analyst View
Company Profile
CIK0001658551
ISINUS03237H1014
CUSIP03237H101
Phone617 682 0917
Address43 Thorndike Street, Cambridge, MA, 02141, US
SEC EDGAR